BET BD2-IN-1

BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC50=1.6 nM) . BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research[1].

Product Specifications

CAS Number

[2677039-24-4]

UNSPSC

12352005

Target

Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Epigenetics

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bet-bd2-in-1.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=CC=CC(CN2C3=C(C=C4C5=C2C=CC=C5C(N4C)=O)C=CC=C3)=C1)NC6CCN(CC6)C

Molecular Formula

C30H30N4O2

Molecular Weight

478.58

References & Citations

[1]Wang Z, et al. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases. J Med Chem. 2023 Aug 10;66 (15) :10824-10848.